For Rare Disease Day, in an AOP Health-sponsored podcast Melissa Fellner, VP of Global Therapeutic Areas, Commercial Operations, discussed their work.
SCOPE 2026 was dominated by one big topic: AI. You couldn’t walk five steps without hearing about something that AI was going to fix.
AI scientists will no longer operate at the margins of life sciences research - they'll become essential collaborators in the labs of tomorrow.
On the sidelines of JPM, Daiichi-Sankyo US CEO Ken Keller told pharmaphorum about the company's big year and its long-term strategy in ADCs.
As reported in January this year, the United States Centers for Medicare & Medicaid Services (CMS) rolled out $10 billion in
Editor's Picks
